苯二氮平类类药物市场 - 按产品、药物类别、适应症、给药途径、配销通路、全球预测 2024 - 2032 年

Benzodiazepine Drugs Market - By Product, Drug Class, Indication, Route of Administration, Distribution Channel, Global Forecast 2024 - 2032

出版日期: 2024年03月08日 | 出版商:

Global Market Insights Inc. | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于焦虑症病例增加、对心理健康问题的认识不断提高以及老年人口不断扩大，苯二氮平类类药物市场预计在 2024 年至 2032 年期间复合年增长率为 3.9%。

据世界卫生组织称，目前世界上大约 4% 的人口受到焦虑症的影响。在全球范围内，焦虑症的发生率增加，包括恐慌症和社交焦虑症等疾病。盛行率激增归因于多种因素，包括社会压力、经济不确定性和生活方式的改变。随着人们寻求有效的治疗方案来控制症状和改善生活质量，对以其抗焦虑特性而闻名的苯二氮平类药物的需求持续上升。此外，苯二氮平类药物作为治疗焦虑症的第一线药物干预措施的出现进一步促进了其广泛使用，推动了製药业的市场成长。

苯二氮平类类药物产业根据产品、药物类别、适应症、给药途径、配销通路和地区进行分类。

由于地西泮的抗焦虑、镇静和肌肉鬆弛特性及其在治疗焦虑症、肌肉痉挛和酒精戒断症状中的应用，地西泮细分市场将在 2032 年实现健康成长。其治疗各种病症的多功能性、有效性和相对较低的成本为其赢得了巨大的市场份额。此外，仿製药的出现进一步推动了地西泮的采用。

由于高压力水平、生活方式的改变和人口老化，到 2032 年，失眠领域将在苯二氮平类药物市场占据相当大的份额。苯二氮平类药物，包括地西泮和其他衍生物，如替马西泮和劳拉西泮，由于其镇静催眠特性，通常用于短期治疗失眠。然而，对其潜在的依赖性和不良反应的担忧导致了更严格的审查和对替代治疗方式的探索。

在庞大的人口基础、精神健康疾病盛行率上升以及医疗基础设施改善的推动下，亚太地区苯二氮平类药物产业将于 2024 年至 2032 年快速成长。此外，可支配收入水准的提高和对精神健康疾病的认识不断提高，进一步促进了苯二氮平类药物的使用。中国、印度和日本等国家可能处于该地区市场成长的前沿。

主要动向：按地区
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 中东和非洲其他地区

第 11 章：公司简介

AbbVie Inc.
Amneal Pharmaceuticals LLC.
Bausch Health Companies Inc.
Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc.
Hikma Pharmaceuticals PLC
Mylan N.V.
Novartis AG
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.

简介目录

Product Code: 8454

The Benzodiazepine Drugs Market is expected to garner a CAGR of 3.9% during 2024-2032, driven by rising cases of anxiety disorders, increasing awareness regarding mental health issues, and expanding geriatric population.

According to WHO, approximately 4% of the world's population is currently affected by anxiety disorders. Across the globe, there has been an increase in the incidence of anxiety disorders, including conditions like panic disorder and social anxiety disorder. This surge in prevalence is attributed to various factors, including societal stressors, economic uncertainties, and lifestyle changes. As individuals seek effective treatment options to manage their symptoms and improve their quality of life, the demand for benzodiazepine drugs, known for their anxiolytic properties, continues to escalate. Additionally, the availability of benzodiazepines as a first-line pharmacological intervention for anxiety disorders further contributes to their widespread usage, driving market growth in the pharmaceutical sector.

The Benzodiazepine Drugs industry is classified based on product, drug class, indication, route of administration, distribution channel, and region.

The Diazepam segment will record a healthy growth rate through 2032, owing to the anxiolytic, sedative, and muscle relaxant properties of diazepam and its usage in the management of anxiety disorders, muscle spasms, and alcohol withdrawal symptoms. Its versatility in treating various conditions, in line with its effectiveness and relatively low cost, has contributed to its significant market share. Moreover, the availability of generic formulations has further propelled the adoption of diazepam.

The insomnia segment will amass a decent benzodiazepine drugs market share by 2032, attributed to high stress levels, lifestyle changes, and the growing aging population. Benzodiazepines, including diazepam and other derivatives such as temazepam and lorazepam, are commonly prescribed for short-term management of insomnia due to their sedative-hypnotic properties. However, concerns regarding their potential for dependency and adverse effects have led to greater scrutiny and the exploration of alternative treatment modalities.

Asia Pacific Benzodiazepine Drugs Industry will grow rapidly from 2024 to 2032, driven by a large population base, increasing prevalence of mental health disorders, and improving healthcare infrastructure. Moreover, the rising disposable income levels and growing awareness regarding mental health ailments are further contributing to the uptake of benzodiazepine drugs. Countries such as China, India, and Japan could be at the forefront of market growth in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of anxiety disorders
  - 3.2.1.2 Rising geriatric population
  - 3.2.1.3 Increased incidence of insomnia
  - 3.2.1.4 Advancements in drug formulations
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Associated side effects
  - 3.2.2.2 Abuse potential and regulatory restrictions
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Million)

5.1 Key trends
5.2 Alprazolam
5.3 Diazepam
5.4 Lorazepam
5.5 Clonazepam
5.6 Temazepam
5.7 Oxazepam
5.8 Chlordiazepoxide
5.9 Other products

Chapter 6 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Million)

6.1 Key trends
6.2 Ultra-short acting
6.3 Short acting
6.4 Long acting

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Million)

7.1 Key trends
7.2 Anxiety
7.3 Insomnia
7.4 Alcohol withdrawal
7.5 Seizures
7.6 Other indications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Million)

8.1 Key trends
8.2 Oral
8.3 Parenteral
8.4 Other routes of administration

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

9.1 Key trends
9.2 Hospital pharmacy
9.3 Retail drug stores
9.4 Online pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

10.1 Key trends, by region
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa